Intelligence / Healthtech / New Clinical Trials / Pfizer
Clinicaltrial registered9 Nov 2026
Pfizer
9 Nov 2026: Trial registered · A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 9 Nov 2026
- Title
- A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Study Type
- Observational
- Status
- Not Yet Recruiting
- Reference
- NCT07927023
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Pfizer
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Pfizer in our registers.
12 NovPfizertrial registered · HealthtechClinical12 NovPfizertrial registered · HealthtechClinical12 NovPfizertrial registered · HealthtechClinical9 NovPfizertrial registered · HealthtechClinical5 NovPfizertrial registered · HealthtechClinical4 NovPfizertrial registered · HealthtechClinical2 NovPfizertrial registered · HealthtechClinical30 OctPfizertrial registered · HealthtechClinical29 OctPfizertrial registered · HealthtechClinical28 OctPfizertrial registered · HealthtechClinical27 OctPfizertrial registered · HealthtechClinical27 OctPfizertrial registered · HealthtechClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.